title: Candidate biomarkers for erythropoietin response in end-stage renal disease.
abstract: Hyporesponsiveness to erythropoiesis-stimulating agents (ESAs) is important clinically and economically. Escalation of dose may produce harm. Post hoc analyses of clinical trials showed that responsiveness could be predicted by hemoglobin response to a fixed dose escalation. This maneuver requires weeks to months. The study by Merchant et al. offers promise that peptidomic analyses of patient sera and mass spectrometry can identify biomarkers of both responsiveness and resistance to ESAs.
authors.affiliation: Division of Nephrology and Hypertension, Henry Ford Hospital, Detroit, Michigan 48202, USA. Abesara1@hfhs.org
authors.forename: Anatole
authors.initials: A
authors.lastname: Besarab
authors.forename: Jerry
authors.initials: J
authors.lastname: Yee
mesh_terms: D015415:Biomarkers / Q000097:blood*; D004921:Erythropoietin / Q000009:adverse effects / Q000627:therapeutic use*; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000188:drug therapy*; D006435:Renal Dialysis
chemical_list: D015415:Biomarkers; D006454:Hemoglobins; D004921:Erythropoietin